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Baltimore, Maryland
Positron emission tomography (PET) is a powerful, quantitative imaging modality that has been used for de-
cades to noninvasively investigate cardiovascular biology and physiology. Due to limited availability, method-
ologic complexity, and high costs, it has long been seen as a research tool and as a reference method for valida-
tion of other diagnostic approaches. This perception, fortunately, has changed significantly within recent years.
Increasing diversity of therapeutic options for coronary artery disease, and increasing specificity of novel thera-
pies for certain biologic pathways, has resulted in a clinical need for more accurate and specific diagnostic tech-
niques. At the same time, the number of PET centers continues to grow, stimulated by PET’s success in oncol-
ogy. Methodologic advances as well as improved radiotracer availability have further contributed to more
widespread use. Evidence for diagnostic and prognostic usefulness of myocardial perfusion and viability assess-
ment by PET is increasing. Some studies suggest overall cost-effectiveness of the technique despite higher costs
of a single study, because unnecessary follow-up procedures can be avoided. The advent of hybrid PET-computed
tomography (CT), which enables integration of PET-derived biologic information with multislice CT-derived mor-
phologic information, and the key role of PET in the development and translation of novel molecular-targeted
imaging compounds, have further contributed to more widespread acceptance. Today, PET promises to play a
leading diagnostic role on the pathway toward a future of high-powered, comprehensive, personalized, cardiovas-
cular medicine. This review summarizes the state-of-the-art in current imaging methodology and clinical applica-
tion, and outlines novel developments and future directions. (J Am Coll Cardiol 2009;54:1–15) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.065t
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cThat is gold which is worth gold.
—George Herbert, English poet, 1593 to 1633 (1)
ince the introduction of the first positron emission tomogra-
hy (PET) scanner in 1975 (2), PET has been used for
oninvasive imaging of the heart (3,4). It has often helped
eveal groundbreaking basic science in the areas of myocardial
lood flow regulation (5–9), myocardial substrate metabolism
10–14), and cardiac autonomic innervation (15–18).
Due to its inherently quantitative nature, its superior detec-
ion sensitivity, and its advantageous spatial and temporal
esolution over conventional nuclear techniques, PET has been
onsidered a “gold standard” for noninvasive assessment of
yocardial perfusion and viability. In the past, multiple new
maging techniques have been validated with PET as the gold
tandard (19–26). And in the near future, PET imaging is
xpected to play a key role in the introduction of novel,
olecular-targeted imaging approaches (27,28).
rom the Division of Nuclear Medicine/PET, Russell H. Morgan Department of
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009, accepted February 23, 2009.Despite its undisputed value as a high-end diagnostic
ool, PET has struggled for many years to expand from its
ole as a reference standard to broader clinical application.
mpeding factors have been the complexity and limited
vailability of PET cameras, the complexity of production
nd delivery of short-lived positron-emitting radiotracers,
nd concerns related to the high cost of the test.
Approval of PET radiotracers for clinical cardiac application
y the U.S. Food and Drug Administration (FDA) in 1989
nd 2000, followed by reimbursement of their use for myocar-
ial perfusion and viability imaging by the Centers for Medi-
are and Medicaid Services (CMS) (Table 1), were important
rst steps toward clinical success (29). In recent years, contin-
ous improvement of scanner systems, commercial marketing
f the tracers fluorodeoxyglucose (FDG) and rubidium-82
82Rb), and increasing availability of the technique, mostly due
o its tremendous success in oncology, have all contributed to a
apid growth of PET for clinical cardiac imaging.
Today, many leading nuclear cardiology institutions run
igh-throughput PET programs and create further evidence
or its clinical usefulness (30–33). Large sample-size studies
nd randomized trials are underway or have been published
34). Industry is introducing novel radiotracers for future
ommercialization (35). Technical advances such as hybrid
maging systems (36) and molecular-targeted probes (28)
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Cardiac PET June 30, 2009:1–15continue to drive the field for-
ward. Based on these develop-
ments, the notion that PET is
“worth gold” to advance cardio-
vascular medicine stays strong.
Part 1: State-of-the-Art
in Imaging Technology
Strengths of PET methodology.
Beta () decay of a nucleus re-
sults in emission of a positron,
which rapidly annihilates with an
electron, giving off two 511-keV
photons, which travel in opposite
directions. The basic principle of
PET is detection of these pho-
tons as coincidences in a ring
scanner (Fig. 1A). The spatial
resolution of reconstructed clini-
cal PET images is currently in
the range of 4 to 7 mm (37), and
it is superior to conventional nu-
lear imaging techniques. Superior detection sensitivity
llows for identification of radiotracer at nano- to picomolar
oncentrations. PET also has high temporal resolution,
hich allows for creation of dynamic imaging sequences to
escribe tracer kinetics. Together with readily available
orrection algorithms for photon attenuation, scatter, and
andom events, these characteristics make PET a truly
uantitative imaging tool that measures absolute concentra-
ions of radioactivity in the body and allows for kinetic
odeling of physiologic parameters such as absolute myo-
ardial blood flow or glucose use.
In recent years, several technical innovations have con-
ributed to a steady improvement in the performance of
linical PET systems (Figs. 1B to 1D). New detector
aterials have enhanced coincidence detection yield and
educed system dead time (37). Three- rather than
-dimensional coincidence detection is being used to max-
mize count yield, improve image statistics, and/or reduce
njected dose (38,39). Reconstruction algorithms have been
ntroduced that decrease noise and correct for geometry-
elated loss of resolution with increasing distance from the
enter of the field-of-view (40). All of these advances make
mplementation of the time-of-flight (the difference be-
ween arrivals of coincidence photons on both sides of the
Abbreviations
and Acronyms
CAD  coronary artery
disease
CFR  coronary flow
reserve
CMS  Centers for
Medicare and Medicaid
Services
CT  computed
tomography
FDA  Food and Drug
Administration
FDG  fluorodeoxyglucose
MBF  myocardial blood
flow
PET  positron emission
tomography
SPECT  single-photon
emission computed
tomography
DA-Approved Cardiac PET Tracers
Table 1 FDA-Approved Cardiac PET Tracers
Tracer Half-Life
Tissue Positron
Range (mm) Myocardi
82Rb 78 s 2.6 Na/K-ATPase
13NH3 10 min 0.7 Diffusion/met
18F-FDG 110 min 0.2 Glucose transpMS  Centers for Medicare and Medicaid Services; FDA  Food and Drug Administration; FDG  fluorod
b  rubidium.etector ring, which is in the range of picoseconds) close to
ecoming a clinical reality. This will increase spatial infor-
ation and improve the signal/noise ratio (37).
On the acquisition side, collection of data in list mode has
ecome available for routine use, allowing for multiple
mage reconstructions from a single dataset, including static,
ated, and dynamic images (Fig. 2). This increases flexibility
nd provides various options for advanced image processing.
lectrocardiogram-gated datasets can be created for com-
lementary functional analysis (41). The addition of respi-
atory gating may allow for creation of “motion-frozen”
mages, which will reduce distortion and facilitate correction
or respiratory misalignment (42).
These advantages may be combined with creation of dy-
amic imaging sequences for routine measurement of tracer
inetics and noninvasive absolute quantification of biological
nd physiological processes by compartmental modeling (43).
ositron-emitting radiotracers for cardiac imaging.
able 1 lists current FDA-approved tracers for cardiac PET,
nd Table 2 lists other cardiac tracers that are not FDA
pproved but have been successfully applied in humans.
ET PERFUSION TRACERS. FDA-approved 82Rb and 13N-
mmonia (13NH3) allow for short imaging protocols and
ame-day repeated studies due to their short half-lives. A PET
erfusion study can be readily accomplished in a fraction of the
ime necessary for single-photon emission tomography
SPECT) myocardial perfusion imaging (29,44). 13NH3 has a
rst-pass extraction of 80% and requires energy for myocardial
etention. The images are of high quality and resolution, and
ptake is linear over a wide range of myocardial blood flow
xcept at very high flow rates (45). Imaging with 13NH3
equires either an on-site cyclotron or close proximity to a
egional radiopharmaceutical production center.
82Rb is a potassium analog that has a first-pass extraction
f 65% and also requires energy for myocardial uptake via
a/K-ATPase. With 82Rb, the extraction fraction decreases
n a nonlinear manner with increasing blood flow, and this
ffect is more pronounced when compared with ammonia,
lthough still superior when compared with technetium-
9m (99mTc)-labeled SPECT compounds (46,47). Image
esolution and quality are somewhat compromised due to
he high energy of positrons emitted during the decay of
2Rb and due to lower count rates as a result of the
ltrashort half-life (Fig. 3). A major advantage of 82Rb over
3NH3 is that it is produced by an
82Sr/82Rb generator
ke Mechanism FDA Approval
CMS Reimbursement
Since
ion) December 1989 March 1995
trapping (perfusion) March 2000 October 2003
xokinase (viability) March 2000 July 2001al Upta
(perfus
abolic
ort/heeoxyglucose; Na/K-ATPase  sodium/potassium-ATPase; PET  positron emission tomography;
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June 30, 2009:1–15 Cardiac PETithout the need for a cyclotron. Commercial availability of
2Rb generators in the U.S. has been considered a key
lement for more widespread application of clinical myo-
ardial perfusion PET.
Another well-established perfusion tracer, H2
15O, is
otentially superior to 82Rb and 13NH3 because it is
e +
e -
Positron
(Neutrino)
Electron(511keV) γ (511keV)
A
B
t2
t1
TOF
No TOF
C D
γ
Figure 1 Advances in PET Technology
(A) Basic positron emission tomography (PET) principle: a positron (e) is
emitted from the atomic nucleus together with a neutrino. The positron moves
randomly through the surrounding matter, where it hits electrons (e) until it
finally loses enough energy to interact with a single electron. This process,
called “annihilation,” results in 2 diametrically emitted photons with an energy
of 511 keV each. These photons are detected as coincidences in the detector
ring of the PET camera. (B) Traditional 2-dimensional imaging (left) uses only
coincidences that occur within the same axial detector ring. Adjacent detector
rings are separated by septa. Advanced 3-dimensional imaging (right) uses
coincidences from all possible detector pairs. This increases sensitivity and
count density but is demanding and requires correction for the higher amount
of scatter and inhomogeneity at the axial edge of the field of view. (C) Inhomo-
geneity of in-plane spatial resolution is a function of a broader line of response
for detector pairs toward the edge of the field of view (pink line vs. blue line).
System matrix resolution modeling has been developed to correct for this
effect and increase resolution. (D) Time-of-flight (TOF) PET increases the signal-
to-noise ratio. This has become a reality since the introduction of novel detec-
tors with high time resolution of 500 picoseconds or less. In traditional non-
TOF PET, the only spatial information is derived from the line of response of
the detector pair (green). The system has to assume that the annihilation may
have occurred anywhere along this line of response. However, if TOF informa-
tion is available, location of annihilation can be narrowed to several centime-
ters along the line of response (red), by taking into account the time difference
between arrivals of coincidence photons at opposite detectors (t1–t2).etabolically inert and freely diffusible across cell mem- hranes. However, the tracer is not accumulated in myocar-
ium and instead reaches equilibrium between extra- and
ntravascular compartments. Images of regional myocardial
erfusion are not readily obtained, and processing for blood
ool subtraction is needed (6). The lack of FDA approval
as limited this compound to research applications in the U.S.
ET VIABILITY TRACERS. 18F-FDG is an FDA-approved
lucose analogue that is widely available due to its success as
metabolic imaging tracer in clinical oncology. The tracer is
ell established to determine myocardial glucose use as an
ndicator of myocardial viability. Increased FDG uptake can
e observed in ischemic tissue; markedly reduced or absent
ptake indicates scar formation (11,48).
FDG uptake is heterogeneous in normal myocardium in
he fasting state, so oral glucose loading, nicotinic acid
erivatives, or infusion of insulin and glucose have been
sed to enhance myocardial FDG uptake (44,49). Images
btained in nondiabetic patients and in patients with
oninsulin-dependent diabetes are of higher quality after
dditional insulin infusion than those obtained after oral
lucose loading alone. Bolus injections of insulin have been
uggested (44,50). When such protocols for patient prepa-
ation are followed, cardiac FDG images are generally of
igh diagnostic quality.
adiation exposure. Radiation exposure from cardiac im-
ging procedures has increasingly become a matter of
iscussion (51). An in-depth review of this topic is beyond
he scope of this article, and the interested reader is referred
o dedicated literature (51). It should be noted, however,
hat positron emitting tracers typically provide less radiation
urden to the patient when compared with SPECT tracers
sed for the same diagnostic purpose, which is, in part, due
o their much shorter half-lives. Also, the radiation burden
o staff involved in cardiac PET imaging has been investi-
ated, and due to differences in radiotracer administration,
can acquisition, and stress-testing tasks, doses with PET
eem to be lower for staff (as for patients) when compared
ith single-photon emitting tracers (52).
art 2: State-of-the-Art in Clinical Application
yocardial perfusion. DIAGNOSIS OF CORONARY ARTERY
ISEASE (CAD). In a 2005 review, 8 studies that compared
erfusion PET with coronary angiography, representing a
otal of nearly 800 patients, were summarized, and a mean
ensitivity of 93% and specificity of 92% for detection of
ignificant CAD were observed (29). A more recent review,
eporting a weighted sensitivity of 90% and specificity of
9% from 9 studies including 877 patients, scanned mostly
ith 82Rb PET, confirmed these results (36). For detection
f myocardial ischemia, myocardial perfusion PET is con-
idered to have superior diagnostic accuracy when compared
ith the more widely available and more frequently used
PECT technique (Fig. 4).
Available published reports comparing PET and SPECTave also been recently reviewed (36). The robust methods
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Cardiac PET June 30, 2009:1–15or attenuation correction with PET reduce the number of
alse-positive scans due to attenuation artefacts, and speci-
city is increased. This is of particular importance in obese
opulations and women, where attenuation artefacts are
requent. Perfusion PET also tends to be more sensitive
han SPECT, which can be explained by better spatial
esolution and better tracer extraction at high flow, allowing
or detection of more subtle perfusion abnormalities. How-
ver, the existing literature comparing SPECT and PET
as either been published before 1992 or compared both
echniques in different, retrospectively matched groups. A
rospective head-to-head comparison or randomized study
sing current state-of-the-art for both techniques is missing
nd would be desirable to further support the superiority
f PET.
ROGNOSTIC VALUE. Although meta-analyses confirm a very
igh diagnostic accuracy, it should be emphasized that the
reatest value of perfusion imaging is considered to be its
otential to predict adverse cardiac events (53). This incre-
ental outcome information has been shown to be useful as
gatekeeper for invasive procedures and as a guide to
ppropriate therapy based on individual risk. Studies in very
arge patient groups have supported the incremental prog-
ostic value for SPECT perfusion imaging, and confirma-
Time after injection
R
espiratory
 
cycle
Ca
rdi
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cy
cle
Ca
rdi
ac
cy
cle
A  Static
C  ECG-Gated
ED
ED
ES
Prescan delay
Figure 2 Multidimensional List-Mode PET Acquisition
Scanner coincidences are continuously recorded along with information about the
breathing position (optional). Data can then be resampled in multiple formats at a
all information after a pre-defined pre-scan delay (delay time after tracer injection).
times after injection. This is used for tracer kinetic analysis. (C) Electrocardiograp
ventricular function. (D) Respiratory gated images can be obtained at different pha
tole; ES  end systole; EXSP  expiratory phase; INSP  inspiratory phase; PET ory data for myocardial perfusion PET are also available. In pne study, 685 patients were scanned with dipyridamole
2Rb PET and follow-up was obtained over a mean of 41
onths. The annual mortality rate for a normal scan was
.9%; it was 4.3% for an abnormal scan. After a multivariate
nalysis, PET results had an independent and incremental
rognostic value (54). In a more recent study in 367
atients, 3 groups with different stress perfusion abnormal-
ties (normal, mild, moderate to severe) had annual rates of
ard event of 0.4%, 2.3%, and 7%, respectively, and PET
ata were the strongest predictors of total cardiac events. In
bese patients, a preferred target group for PET imaging
nd a group of individuals at higher risk, the annual total
vent rate was 11% with an abnormal scan and 1.5% with a
ormal scan (32). Another very recent study confirmed the
rognostic value of dipyridamole 82Rb PET in 1,441 pa-
ients with suspected or known CAD, and it demonstrated
n incremental value of stress left ventricular ejection
raction from gated PET (55).
BSOLUTE FLOW QUANTIFICATION. The ability to quantify
yocardial blood flow (MBF) and coronary flow reserve
CFR) in absolute terms is another powerful feature of
ET. This is achieved by compartmental modeling of
ultiframe dynamic acquisitions (47,56–60), and it has
nitially been limited to research applications in selected
Time after injection
R
espiratory
 
  Dynamic
  Respiratory Gating
INSP
EXSP
EXSP
fter the start of acquisition, the electrocardiographic signal, and the signal about
e of the acquisition. (A) High-count static images are reconstructed by summing
ynamic imaging sequences are obtained by serial temporal sampling at different
gated images are obtained at multiple phases of the cardiac cycle to assess
f the breathing cycle in order to correct for respiratory motion. ED  end dias-
tron emission tomography.cycle
B
D
time a
ny tim
(B) D
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posiopulations. Early studies showed adverse effects on CFR
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June 30, 2009:1–15 Cardiac PETor multiple risk factors such as hyperlipidemia, diabetes, or
moking and supported the beneficial effects of risk-factor
odifications and novel medical therapies (61–73). These
tudies have contributed to a paradigm shift in the percep-
ion of CAD, away from a pure macroscopic view of luminal
tenoses and toward an emphasis on microcirculation and
82Rb
13NH3
18F-FBnTP
SA VLA HLA
Figure 3 PET Perfusion Tracers
Tomographic positron emission tomography (PET) images of myocardial perfusion
after administration of adenosine using 3 different tracers, the Food and Drug
Administration-approved agents 82rubidium (82Rb) (top) and 13N-ammonia (13NH3)
(middle), and the novel compound 18F-fluorobenzyl-triphenylphosphonium (18F-
FBnTP) (bottom). All images were obtained in a dog model of hemodynamically
relevant left circumflex coronary artery stenosis, resulting in reduced perfusion of
inferolateral myocardium, as shown by all 3 tracers. Since the canine cardiac anat-
omy is different from human anatomy, the septum is displayed more superiorly in
short axis (SA) images. HLA  horizontal long axis; VLA  vertical long axis.
ther Cardiac PET Tracersith Reported Human Application
Table 2 Other Cardiac PET TracersWith Reported Human Application
Tracer Half-Life, min Myocardial Uptake Mechanism
H2
15O 2 Free diffusion (perfusion)
62Cu-PTSM 9.7 Intracellular binding (perfusion)
18F-BMS747158 110 Mitochondrial binding (perfusion)
11C-acetate 20 Krebs cycle flux, oxidative metabolism
11C-palmitate 20 Fatty acid metabolism
11C-glucose 20 Glucose metabolism
18F-FTHA 110 Fatty acid uptake
11C-hydroxyephedrine 20 Sympathetic neuronal catecholamine
uptake
11C-epinephrine 20 Sympathetic neuronal catecholamine
storage
11C-phenylephrine 20 Sympathetic neuronal catecholamine
turnover
18F-fluorodopamine 110 Sympathetic neuronal uptake and
function
11C-CGP12177 20 -adrenergic receptor density
11C-CGP12388 20 -adrenergic receptor density
11C-GB67 20 1-adrenergic receptor density
11C-MQNB 20 Muscarinic receptor density
THA  fluorothiaheptadecanoic acid; MQNB  methylquinuclidinyl benzilate; PET  positron
mission tomography; PTSM  pyruvaldehyde bis(N4-methylthiosemicarbazone).sndothelial function. These are both determinants of CFR
nd MBF and are key mediators of disease progression and
isk. Several studies have suggested the prognostic value of
uantitative PET measurements of MBF and CFR for
rogression toward clinically overt CAD (74) and in idio-
athic and hypertropic cardiomyopathies (75,76).
The growing use of myocardial perfusion PET for the
linical workup of CAD has resulted in stronger efforts to
nclude absolute flow quantification in the analysis of
linical studies. Technical improvements (i.e., more rapid
nd robust processing and analysis of dynamic data) have
xpedited these efforts. Algorithms for the most frequently
sed clinical cardiac PET tracer, 82Rb, are increasingly
eing validated and used (43,47,60). Quantitative flow
easurements may be useful and complementary to the
urrent standard of visual/semiquantitative analysis. Their
eproducibility has been demonstrated repeatedly (77–79).
hey may be useful for detection and evaluation of extensive
ultivessel CAD with balanced ischemia on qualitative
mages (80) (Fig. 5), evaluation of the significance of a given
esion (81), evaluation of collateral flow (82), identification
f endothelial dysfunction in pre-clinical disease, as well as
eliable monitoring of therapeutic strategies.
UMMARY. Table 3 summarizes the evidence and potential
linical role of PET myocardial perfusion imaging.
yocardial viability. CLINICAL VALUE. Therapeutic deci-
ion making is difficult in patients with advanced CAD and
99mTc-MIBI SPECT 82Rb PET
Stress
Rest
Stress
Rest
A
B
Figure 4 Comparison of PET and SPECT Perfusion Imaging
Shown are matched, representative short-axis slices for single-photon emission
computed tomography (SPECT) (left) and positron emission tomography (PET)
(right) in 2 subjects with suspected coronary artery disease. Panel A illus-
trates improved specificity with PET. A fixed defect in the inferior wall on SPECT
is absent on PET, suggesting the presence of a SPECT attenuation artefact.
Panel B illustrates improved sensitivity with PET. Stress-induced perfusion
defects in the anterior and inferolateral walls (arrows) are more clearly shown
with PET versus SPECT.evere left ventricular dysfunction because revascularization has
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Cardiac PET June 30, 2009:1–15high procedure-related risk. Viability testing has been devel-
ped to serve as a guide to the most appropriate therapy.
nitially, PET techniques played a key role in understanding
he myocardial response to severe ischemic damage and in
stablishing the identification of myocardial viability as a
iagnostic target. Metabolic imaging has been used to support
he notion that assessment of perfusion alone may not be
nough to predict functional recovery after revascularization.
he pathophysiology of hibernating myocardium has been
haracterized by PET imaging as resting hypoperfusion and
ysfunction with preserved glucose metabolism (11) (Fig. 6).
It is now well known that PET, using the metabolic
racer FDG, is accurate to predict improvement of regional
all motion and global left ventricular ejection fraction after
evascularization. When comparing PET with alternative
iability imaging techniques such as low-dose dobutamine
chocardiography, SPECT imaging with perfusion tracers,
r delayed enhancement magnetic resonance imaging, dif-
Qualitative Perfusio
Stress
Rest
SA VLA H
L fo %0010
Stress
Rest
SA VLA
A 
B 
Figure 5 Flow Quantification by PET
Qualitative and quantitative assessment of myocardial perfusion by rest/dipyridam
and (B) in a subject with angiographically proven triple-vessel disease and balance
ual left ventricular (LV) maximum and show no significant regional perfusion hetero
dynamic images (right), are all normalized to the same flow range of 0 to 3 ml/m
reserve. Abbreviations as in Figure 3.erences exist that are mostly related to the pathophysiolog- wcal target of each imaging test. A detailed comparison
etween techniques is beyond the scope of this article, and
eaders are referred to dedicated reviews (83–85).
PET is most predictive of improvement of function after
evascularization when blood flow is reduced by50%, with
elatively high glucose uptake. A recent pooled analysis of
4 studies in 756 patients, demonstrated a weighted mean
ensitivity and specificity of 92% and 63%, respectively, for
egional functional recovery, with positive and negative
redictive values of 74% and 87%, respectively (85).
It has been shown that it is critical to revascularize patients
ith PET-defined hibernating myocardium as soon as possible
ecause improvement is less likely to occur when surgery is
elayed after documentation of dysfunctional but viable myo-
ardium (86). This has recently been confirmed in a large study
nalyzing more than 700 patients who all underwent 18F-FDG
ET. Patients with rapid intervention had significantly better
utcomes when compared with a propensity-matched group
Quantitative Flow
g/nim/lm 30
Polarmaps
1.2 ml/min/g 
Flow Reserve: 1.2
1.0 ml/min/g
LV Average
2.3 ml/min/g 
Flow Reserve: 3.3
0.7 ml/min/g
ress and 82Rb PET (A) in a subject with low likelihood of coronary artery disease,
emia. Qualitative static tomographic images (left) are normalized to the individ-
ty in either case. Polar maps of absolute myocardial blood flow, determined from
nd show significant reduction of stress flow in B, resulting in blunted flown
LA
xaM V
HLA
ole st
d isch
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in/g aith delayed or no intervention (33).
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June 30, 2009:1–15 Cardiac PETOther studies have shown that PET can also be used to
redict improvement of heart failure symptoms and im-
rovement of exercise capacity (87). Several retrospective
tudies have focused on the outcome of patients with
schemic heart disease and ventricular dysfunction relative to
heir PET results and their treatment strategy. A recent
eta-analysis summarized 10 studies in 1,046 patients and
ound annualized mortality rates of 4% for those with viable
yocardium who underwent revascularization versus 17%
or those with viability who did not undergo revasculariza-
ion. The mortality was 6% for those without viability
ndergoing revascularization versus 8% for those without
iability not undergoing revascularization (85).
ANDOMIZED TRIALS. Assessment of myocardial viability by
ET is one of the few diagnostic approaches that have been
xplored in randomized diagnostic studies. Such studies are
ifficult to design because therapeutic decision making
which will influence outcome) is difficult to control. The
eld should be commended for having conducted such
tudies. Despite the strength of randomization, results of
hese studies must be interpreted with caution. Inclusion
riteria as well as management algorithms need to be taken
linical Myocardial Perfusion PET:ummary of Evi ence and Potential Clinical Role
Table 3 Clinical Myocardial Perfusion PET:Summary of Evidence and Potential Clinical Role
Imaging technique High temporal resolution enables dynamic imaging
and absolute blood flow quantification.
Spatial resolution superior to SPECT.
Well-established attenuation correction increases
specificity.
Radiotracers Extraction fraction superior to SPECT tracers (44–46).
Short half-life enables shorter imaging protocols and
lower radiation exposure, but complicates use of
exercise stress (vasodilator stress preferred) (28).
Diagnostic accuracy Meta-analyses suggest sensitivity and specificity for
detection of coronary artery stenosis is around
90% (28,35).
Comparison to SPECT suggests superiority (35), but
recent prospective head-to-head comparison is not
available.
Prognostic value Predictive of risk for cardiac events, supported by
some studies (30,31,54,55). Less evidence to
support PET when compared with SPECT.
Cost-effectiveness Some older studies support cost savings despite high
single-test costs (93,94); more recent analyses are
not available.
Superior accuracy helps avoid unnecessary
subsequent procedures (95).
Randomized trials None available.
Suggestions for
current clinical use
Second-line test after equivocal SPECT or other
equivocal perfusion studies.
First-line test in groups where SPECT is frequently
equivocal (obese patients).
First-line test in situations where quantification and
reproducibility are important (suspected balanced
ischemia, longitudinal follow up studies) (76–78).
Potential future use May be used as first-line test in all cases if diagnostic
superiority to SPECT is confirmed in head-to-head
or randomized trials and if cost-effectiveness is
proven in the present health care environment.
ET  positron emission tomography; SPECT  single-photon emission computed tomography.nto consideration. One early randomized study assignedatients to either SPECT or PET and found no difference
n accuracy between techniques for viability assessment (88).
owever, the study included patients with relatively pre-
erved ejection fractions, where differences between tech-
iques may be minimal.
The benefits of PET are expected to be greater in a target
opulation with severe heart failure and an ejection fraction
elow 35%. A group of patients fulfilling these criteria was
tudied in another recent randomized trial that assigned 430
atients to either management assisted by FDG PET or
tandard care. The study overall showed only a nonsignifi-
ant trend toward reduction in cardiac events for FDG
ET-assisted management versus standard care. But it
eeds to be emphasized that alternative viability testing was
llowed in the control arm and that nonadherence to
ET-based recommendations was found in a significant
ubfraction of patients in the PET arm. Importantly, in
hose who adhered to PET recommendations regarding
herapy, significant survival benefits were observed (34).
lthough PET has been used in large and powerful viability
tudies, the results of these studies are still controversial and
t is difficult to find a unifying conclusion. The evidence in
upport of the usefulness of PET is growing, but the use of
iability imaging at a given center is still defined mostly by
ocal expertise and availability.
UMMARY. Table 4 summarizes the evidence and potential
linical role of PET myocardial viability imaging.
Match
Mismatch
SA VLA HLA
Metabolism
(18F-FDG)
Perfusion(82Rb, Rest)
Perfusion(82Rb, Rest)
Metabolism
(18F-FDG)
Figure 6 PET Perfusion/Metabolism Imaging
for Assessment of Myocardial Viability
(Top) A mismatch with reduced rest perfusion (measured by 82Rb) and pre-
served/increased metabolism (measured by 18F-FDG) is shown in the inferolat-
eral wall, indicating ischemically compromised but viable “hibernating”
myocardium. (Bottom) A matched perfusion/metabolism defect is shown in
the inferior wall, indicating nonviable scar. FDG  18F-deoxyglucose; other
abbreviations as in Figure 3.
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Cardiac PET June 30, 2009:1–15ther clinical applications. Apart from its use in CAD,
ET has also been used for less frequent diseases involving
he heart and cardiovascular system. Low radiation exposure
nd short imaging protocols make it attractive for assess-
ent of perfusion and metabolism in selected pediatric
ardiac patients (89,90). Also, the ability to do whole body
maging in addition to dedicated cardiac imaging makes it
ttractive for evaluation of systemic inflammatory disease
uch as sarcoidosis, in which cardiac involvement is prog-
linical Use of PET Imaging for Assessment ofyo rdial Viability: Summary of Evidence andotential Clinica Role
Table 4
Clinical Use of PET Imaging for Assessment of
Myocardial Viability: Summary of Evidence and
Potential Clinical Role
Imaging technique Spatial resolution superior to SPECT but inferior to
MRI or echocardiography.
Well-established attenuation correction increases
specificity.
Radiotracers Metabolic tracer 18F-FDG indicates preserved
glucose use in ischemically compromised but
viable myocardium.
Should be combined with a perfusion study.
Metabolic preconditioning required (glucose
and/or insulin).
Diagnostic accuracy Meta-analyses suggest sensitivity around 90% and
specificity of 60% to 70% for prediction of
regional functional recovery after
revascularization (83–85).
Targeted biomechanism needs to be considered
for comparison with other techniques
(metabolism may be preserved when
contractile reserve is already absent, explaining
lower specificity but higher sensitivity when
compared with functional techniques using
low-dose dobutamine) (83).
Prognostic value Supported by many retrospective studies (85).
Predictive of functional and symptomatic
improvement.
Better overall outcome for revascularized vs.
nonrevascularized when PET used to determine
viable myocardium.
Cost-effectiveness Limited evidence (guidance to appropriate therapy
may improve medical care and costs).
Randomized trials Randomized comparison to SPECT failed to show
superiority, probably due to inclusion of
patients with higher ejection fraction (88).
PARR2 trial: No significant difference between
PET-assisted and standard care in general, but
significant benefit when PET recommendations
were followed (33).
Suggestions for current
clinical use
Type of viability testing still depends on local
expertise and availability.
First-line test in severely impaired ischemic
LV dysfunction (LVEF 35%); most beneficial
when adherence to results is achieved.
Second-line test if therapeutic decision remains
difficult after a first test.
Potential future use May be used more broadly if cost-effectiveness
is proven.
May be integrated into diagnostic algorithms with
other tests such as MRI or echocardiography,
but requires prospective validation.
DG  fluorine-18-fluoro-deoxyglucose; LV  left ventricular; LVEF  left ventricular ejection
raction; MRI  magnetic resonance imaging; PARR  PET and Recovery Following Revascular-
zation; PET  positron emission tomography; SPECT  single-photon emission computed
omography.ostically very relevant (91,92). most-effectiveness considerations. In cardiology, imaging
ptions are extensive and often redundant. Because financial
esources in health care are increasingly limited, the ques-
ion of cost-effectiveness is crucial. The value of PET as a
esearch tool and as a gold standard for other diagnostic
maging techniques is not in question, but reimbursement
nd general clinical application of the technique is under
ore scrutiny because a PET procedure is more expensive
han other noninvasive procedures.
Looking only at the costs of a single test is a short-
ighted, incomplete approach. Estimation of the total cost
f diagnostic tests for CAD requires consideration of
ndirect and induced costs of management algorithms based
n the test. False positives may result in unnecessary
ubsequent diagnostic or therapeutic procedures, which
arry additional costs and risks. A missed diagnosis due to a
alse-negative test, on the other hand, may result in pre-
entable adverse events that could impair life duration and
uality. A comprehensive analysis of utility has to account
or the impact of medical care on quality as well as quantity
f life.
Patterson et al. (93) used a mathematical model to
ompare cost-effectiveness of exercise electrocardiography,
PECT, PET, and invasive angiography to diagnose CAD.
heir model accounted for costs per effect or cost per utility
nit (including cost of diagnostic and therapeutic measures,
hich included those that yield false-positive results as well
s those that yield false-negative results). They observed
hat PET, despite the high cost of a single test, shows the
owest cost per effect in patients with a pre-test likelihood of
AD below 70%. This was attributed to its superior
iagnostic accuracy and avoidance of false-positive and
alse-negative studies. Only when the pre-test likelihood
as above 70% was direct angiography the most cost-
ffective approach. Gould et al. (94), using a somewhat less
omplex model, had earlier come to similar conclusions, but
oth studies were published more than 13 years ago.
Merhige et al. (95) more recently compared the frequency
f diagnostic arteriography, revascularization, costs, and
-year clinical outcomes in 2,159 patients studied with PET
ith an internal and an external SPECT control group.
hey showed reduced use of downstream invasive proce-
ures when using perfusion PET versus SPECT, which
esulted in lower costs with comparable outcomes.
Similar issues need to be considered for PET imaging of
yocardial viability. The costs of a single test are high, but
he costs and risk of avoidable surgical or interventional
reatment may be even higher. Avoidance of an unnecessary
ypass operation, or even of an unnecessary cardiac trans-
lantation, may justify conducting numerous noninvasive
ests if they are appropriate for guidance of clinical decision
aking. It has clearly been shown that PET assessment of
iability influences decision making (96), and if PET
ecommendations are followed, outcomes will improve (34).
ne study in the United Kingdom applied an economic
odel and compared 3 strategies (bypass for all patients,
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June 30, 2009:1–15 Cardiac PETedical therapy for all patients, and PET-guided decision
or bypass or medical therapy). It was concluded that PET
ay be cost-effective to select patients with poor left
entricular function for coronary artery bypass grafting (97).
Hence, there is some evidence for cost-effectiveness of
ardiac PET in the clinical setting. Factors such as higher
atient throughput and patient comfort due to shorter
maging protocols for PET versus SPECT have not even
een considered in the above analyses. But cost-effectiveness
emains complex and difficult to generalize. Further studies
sing updated clinical algorithms and updated values for
ccuracy and procedure costs are necessary to support the
se of PET in the actual health care environment.
Target populations in which perfusion PET may be
specially cost-effective are obese patients and women,
lthough it should be noted that computed tomography
CT) angiography may emerge as a competitor to PET in
uch situations (98). For viability imaging, end-stage isch-
mic cardiomyopathy may be the most useful situation.
tudying cost-effectiveness in these specific groups in more
etail might further support an efficient clinical use of the
igh-end technique.
art 3: New Developments and Future Directions
ybrid PET-CT: the merging of morphology, function
nd biology. Due to their success in oncology, all currently
ffered PET imaging systems are hybrid PET-CT scanners.
his has brought challenges for cardiac imaging that are
elated mainly to the use of a separate CT for attenuation
orrection of subsequently acquired PET data. Respiratory
r patient motion may result in misalignment of CT and
ET and artificial heterogeneity in CT-attenuation–
orrected cardiac PET images (99). Corrective algorithms
ave been proposed to address this issue (99–101).
More importantly, the advent of hybrid PET-CT has
esulted in the unique opportunity to combine CT-derived
orphologic information with PET-derived functional,
hysiological and biological information. Most PET-CT
canners are now equipped with multislice CT, allowing for
T measurement of coronary calcium and/or CT coronary
ngiography in addition to PET imaging procedures.
Schenker et al. (31) measured myocardial perfusion and
oronary calcium in a single cardiac PET-CT study in 695
atients with an intermediate pre-test likelihood of CAD.
hey observed an increasing prevalence of abnormal PET
ith increasing coronary calcium scores. In about 50% of
ases with very high calcium, myocardial perfusion was
bnormal. But interestingly, abnormal perfusion was also
ound in 16% of patients with absent calcium.
Risk-adjusted survival analysis demonstrated a stepwise
ncrease in cardiac events with increasing calcium scores in
atients with and without ischemia on PET. Among
atients with normal PET myocardial perfusion imaging,
he annualized event rate in patients with no calcium was
ower than in those with high calcium (2.6% vs. 12.3%, tespectively). In patients with ischemia demonstrated on
ET, the annualized event rate in those with no calcium
as also lower than in those with high calcium (8.2% vs.
2.1%). These data suggest that CT calcium scoring and
ET perfusion imaging are complementary for the assess-
ent of cardiovascular risk. Both can be integrated to
tratify patients into different risk-based categories.
There is less evidence at the moment for the integrated
se of CT coronary angiography and perfusion PET,
lthough initial studies suggest that both tests may also be
omplementary rather than competitive. Not all patients
ith obstructive atherosclerosis on CT show ischemia on
ET and, vice versa, not all patients with nonobstructive
AD have no perfusion abnormalities (102).
Contrast-enhanced CT angiography enables the detec-
ion of noncalcified plaque and, if imaging is repeated
everal minutes after injection, it may allow for detection of
nfarcts by delayed contrast enhancement (103,104). How
his information is best combined with PET for maximiza-
ion of diagnostic and prognostic accuracy will be a matter
f further research in the future. It is likely, however, that
ncreasing availability of 64-slice CT in PET-CT systems,
long with new prospectively gated CT acquisition tech-
iques, which lower radiation exposure for CT angiography
y more than 70% (105), will contribute to a more wide-
pread use in hybrid PET-CT protocols (Fig. 7). Innovative
ntegrated imaging protocols may include CT for morpho-
ogic assessment of coronary arteries and PET for functional
ssessment of myocardial blood flow. A CT delayed en-
ancement study may be done after CT angiography to
dentify the presence or absence of scar (104). This may
bviate the need for a rest perfusion study.
ovel myocardial perfusion tracers. All established PET
erfusion tracers have half-lives that are very short. This
imits their applicability for exercise stress, so clinical pro-
ocols usually use pharmacologic stress with the patient on
he camera table, followed by immediate imaging. Another
onsequence of the short half-lives is the limited availability
f tracers because they require an on-site cyclotron or a
ignificant financial commitment to a strontium/rubidium
enerator, which needs to be replaced every month and
equires high-throughput imaging to be cost-effective. This
as generated interest in fluorine-18-labeled perfusion trac-
rs, which may overcome both problems due to a longer,
10-min half-life. Like FDG, which has already been
uccessfully commercialized, these tracers can be produced
n regional centers for dose-by-dose delivery to multiple
ET sites. Also, they may be injected during exercise stress
ith enough time to move the patient to the camera after
ompletion of the stress protocol.
Currently, data are available on 2 18F-labeled perfusion
ompounds. 18F-BMS747158 is a pyridazinone derivative
hat avidly binds to mitochondrial complex-1 (106). Its
rst-pass extraction fraction is very high at 94% (107), and
t yields high and stable myocardial uptake that is propor-
ional to myocardial blood flow. Myocardial uptake is
g
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Cardiac PET June 30, 2009:1–15reater than that of the SPECT tracers thallium-201 and
9mTc-sestamibi (35). The compound is very promising for
yocardial perfusion PET imaging and it is currently being
ested in clinical phase 1 and 2 studies (Fig. 8).
18F-fluorobenzyl triphenyl phosphonium (FBnTP) is an-
ther compound that is taken up rapidly by myocardium in
roportion to myocardial blood flow (108), with high
ontrast that is superior to the SPECT tracer 99mTc-
etrofosmin. It also targets mitochondria (109) and seems to
e promising for myocardial perfusion imaging (Fig. 3),
lthough, unlike BMS747158, it has not entered clinical
rials yet.
olecular imaging. Cardiovascular molecular imaging is a
apidly emerging discipline that aims toward visualization of
pecific molecular targets and pathways that precede or
nderlie changes in morphology, physiology, and function.
ue to its high detection sensitivity, PET is considered a
ey player in the development and introduction of novel
olecular-targeted imaging approaches. The introduction
f dedicated small animal imaging systems, which allow for
anterior
lateral
Obliqu
Ramus Int
CT Angiography
Figure 7 Hybrid PET-CT Imaging
Integrated assessment of vascular anatomy and myocardial perfusion using hybrid
onset of chest pain after 4 coronary artery bypass grafting. Anterior and lateral v
the left internal mammary artery graft (only clips, indicated by white arrows, are vi
ses). The most severe native coronary lesion is found in a ramus intermedius, wh
soft plaque in the proximal segment). Fusion images of CT anatomy and stress pe
highlight a mild perfusion defect in the territory of the ramus intermedius as the perial in vivo imaging in rodents and facilitate translation of eew diagnostic compounds from experimental to clinical
ractice (Fig. 9), has further contributed to increasing
ecognition of the future potential of molecular imaging in
ardiovascular research and patient care (110–113).
Due to the wide spectrum of novel approaches, a detailed
eview of PET-based molecular imaging is beyond the scope
f this article, and the reader is referred to dedicated articles
27,28,114,115). Some key principles and some examples
re highlighted below. First, molecular imaging places an
mphasis on the diagnosis (and subsequent treatment) of
recursors or the earliest stages of the disease, as opposed to
ts sequelae. Examples are the use of neuronal imaging to
dentify subjects at risk for ventricular arrhythmia (116), the
evelopment of compounds targeting plaque vulnerability be-
ore rupture and subsequent myocardial infarction (117,118),
nd the targeting of biomechanisms that precede left ventric-
lar remodeling and development of heart failure (119,120).
Second, molecular imaging has great potential to facili-
ate discovery and development of novel therapies through
mproved target identification and implementation of more
anterior
lateral
w
dius
Stress PET/CT Fusion
on emission tomography (PET)-computed tomography (CT) in a patient with new
rendered CT angiographic images are shown on the left and indicate failure of
d), and failure of venous grafts (white arrows show occluded aortic anastomo-
urther illustrated by a curved oblique view in the center (yellow arrow shows a
measured by dipyridamole 82Rb PET are shown on the right. Green arrows
e correlate of the patient’s symptoms.e Vie
erme
positr
olume
sualize
ich is f
rfusion
robablfficient end points for clinical trials. Examples are the
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June 30, 2009:1–15 Cardiac PETeasurement of myocardial efficiency to identify the bene-
ts of therapies for heart failure (121,122) and imaging the
eneficial effects of metabolic interventions (123).
18F-BMS747158 PE
Exercise
Stress
Rest
SA VLA
Figure 8 PET-CT Perfusion Imaging at Rest and With Physical E
The injected dose was 1.5 mCi at rest and 3.5 mCi at peak stress. Shown are sta
as well as PET-CT fusion images documenting good alignment of PET and CT (righ
phase-1 study in healthy volunteers. Abbreviations as in Figures 3 and 7.
mc 01
A
B
11C-Ep
Figure 9 Translational Molecular Cardiac PET Imaging
Shown are representative midventricular short-axis slices of myocardial sympathet
For size comparison, images are shown at the same scale (A) and after zooming
ner and the rat heart with a dedicated small animal scanner.Third, visualization of cellular and subcellular target
tructures has contributed to advances in fundamental
ardiac research such as cell trafficking, myocardial regen-
PET-CT
coronalaxial
ise Using the Novel 18F-Labeled Compound BMS747158
enuation-corrected PET images acquired from 5 to 10 min after injection (left),
t and stress studies were obtained on subsequent days as part of a clinical
mc 1mc 01
phrine PET
rvation imaged with 11C-epinephrine, in the healthy human, pig, and rat heart.
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Cardiac PET June 30, 2009:1–15ration, and heart failure-specific functional genomics and
roteomics. Examples are the development of reporter gene
maging techniques (28) and the implementation of cell
abeling for imaging of engraftment after transplantation
28,124).
And fourth, the need to visualize small amounts of
olecular-targeted compounds in small target areas drives
dvances in the imaging sciences such as instrumentation,
econstruction algorithms, and probe design to improve the
etection sensitivity, molecular specificity, and translational
otential of molecular imaging.
The vision is that novel molecular-targeted approaches
ill guide early disease detection and therapeutic/preventive
ecision making based on an individual’s biology. PET as a
ey modality may thereby contribute to further personaliza-
ion of cardiovascular medicine.
ynergies between oncologic and cardiovascular PET.
lthough PET is on the move in cardiovascular medicine
nd new developments are likely to increase its application
nd impact in clinical practice, some similarities and inter-
elationships between its cardiac applications and applica-
ions for tumor imaging should be noted. First, the success
f PET as a key modality in tumor staging and evaluation of
nti-tumor therapy has resulted in dissemination of the
echnique and in improved availability for cardiac imaging.
econd, expensive equipment, such as scanners, radiochem-
stry laboratories, and cyclotrons, is most effectively used
hen it serves multiple areas of PET imaging applications.
nd finally, many existing and novel biologic targets for
ET imaging are important not only in heart and vessels,
ut also in tumors (Table 5). This is highly relevant not only
ecause advances in tumor biology may help advance car-
iovascular biology via improved understanding of related
iomechanisms, but also because multiple applications in
eart, vessels, and tumors will be helpful to stimulate
nterest in commercialization of compounds with a broader
pectrum of target groups.
ummary and Conclusions
ardiac PET is a powerful, quantitative, noninvasive imag-
ng technique that is increasingly penetrating the clinical
rena. For clinical assessment of myocardial perfusion and
iability, evidence for diagnostic and prognostic usefulness is
ncreasing and cost-effectiveness due to high accuracy de-
pite high single-test costs is suggested. The advent of
ybrid imaging enables routine combination of PET with
Examples of Common Imaging Targets in Myoca
Table 5 Examples of Common Imaging Targ
Biologic target Myocardium
Glucose use 1 (when dama
Apoptosis 1 (when dama
Integrin expression/angiogenesis 1 (when dama
Matrix metalloproteinase expression 1 (when damaT-derived morphologic parameters. New molecular imag-ng compounds will be key elements in the emerging
aradigm of personalized medicine.
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